NICE National Institute for
Health and Care Excellence

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Diagnosis and management of Parkinson's disease in adults

2 List of modelling questions

Review questions by scope area	Review Questions
	RQ15: In people for whom deep brain stimulation (DBS) and levodopa–carbidopa intestinal gel (LCIG) are treatment options, what is the comparative effectiveness of DBS, LCIG, and best medical treatment?
	RQ17: In people who are contraindicated for deep brain stimulation, what is the effectiveness of levodopa–carbidopa intestinal gel (LCIG) plus best medical therapy compared to best medical therapy alone?
	RQ18: In people who are contraindicated for levodopa–carbidopa intestinal gel (LCIG), what is the effectiveness of deep brain surgery plus best medical therapy, compared to best medical therapy alone?
Population	People with advanced, levodopa-sensitive Parkinson's disease whose symptoms are no longer controlled using available combinations of conventional Parkinson medicinal products.
Interventions and comparators considered for inclusion	DBS LCIG Best medical therapy (which may include continuous subcutaneous apomorphine)
Perspective	'Health outcomes in NHS settings' (NHS+PSS costs)
Outcomes	Cost per QALY
Type of analysis	Lifetime cost–utility analysis
Issues to note	